Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 <scp>POETYK PSO</scp>‐1, <scp>PSO</scp>‐2 and long‐term extension trials

Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.

Authors

Institutions

Publication Details

Journal
Journal of the European Academy of Dermatology and Venereology
Published
2025-03-06
DOI
https://doi.org/10.1111/jdv.20553
Citations
18
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
14.35
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Matthew J. Colombo, Kim Papp, Victoria Berger, Georgene Schroeder et al.
18 citations
Journal of the European Academy of Dermatology and Venereology
Psoriasis: Treatment and Pathogenesis
14.35
article

Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials

Matthew J. Colombo, Kim Papp, Victoria Berger, Georgene Schroeder, April Wang Armstrong, Joe Zhuo, Howard Sofen, C. Paul, Richard Bruce Warren, Akimichi Morita, Diamant Thaçi, Julie Scotto, Bruce E Strober, Subhashis Banerjee, John Vaile, Eleni Vritzali, Mark Lebwohl
article en
18 citations

Abstract

Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.

Journal of the European Academy of Dermatology and VenereologyVol. 39(7)
Université Toulouse III - Paul Sabatier (FR), University of California, Los Angeles (US), University of Toronto (CA), Manchester Academic Health Science Centre (GB), Northern Health and Social Care Trust (GB), Yale University (US), Nagoya City University (JP), Bristol-Myers Squibb (United States) (US), Manchester University NHS Foundation Trust (GB), Probity Medical Research (CA), Hôpital Larrey (FR), Central Dermatology (US), NIHR Manchester Biomedical Research Centre (GB), University of Lübeck (DE), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 1%
Psoriasis: Treatment and Pathogenesis
14.35
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.